SCHEMBL22979180

SCHEMBL22979180

O=C1NCCNC[C@H]1Nc1nc2c(C(F)(F)F)cccc2c2nc(-c3cnn(C4CC4)c3)nn12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K3 Q8IVH8 2/20 0.32
CCNT1 O60563 1/20 0.32
CCNK O75909 1/20 0.32
CDK7 P50613 1/20 0.32
CDK9 P50750 1/20 0.32
CCNH P51946 1/20 0.32
MNAT1 P51948 1/20 0.32
CDK12 Q9NYV4 1/20 0.32
SOS1 Q07889 1/20 0.32
TLR8 Q9NR97 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP3A5 P20815 2/20 0.32
CYP3A7 P24462 2/20 0.32
CYP2C19 P33261 2/20 0.32
PDK4 Q16654 2/20 0.32
CYP3A43 Q9HB55 2/20 0.32
MAP3K5 Q99683 1/20 0.32
KHK P50053 5/20 0.32
MET P08581 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22979833 1.00 MAP4K3 (0.32) MAP4K3CCNT1CCNKCDK7CDK9
SCHEMBL29645628 1.00 MAP4K3 (0.32) MAP4K3CCNT1CCNKCDK7CDK9
SCHEMBL22988396 0.92 CCNK (0.38) CCNT1CCNKCDK7CDK9CCNH
SCHEMBL29645793 0.92 CCNK (0.38) CCNT1CCNKCDK7CDK9CCNH
SCHEMBL22979395 0.90 HDAC1 (0.35) TLR8CYP1A2CYP3A4CYP3A5CYP3A7
SCHEMBL22988441 0.90 PDE3B (0.33) CCNT1CCNKCDK7CDK9CCNH
SCHEMBL29645522 0.90 PDE3B (0.33) CCNT1CCNKCDK7CDK9CCNH
SCHEMBL22979392 0.90 PDE3B (0.33) CCNT1CCNKCDK7CDK9CCNH
SCHEMBL22988292 0.89 CYP1A2 (0.33) MAP4K3CYP1A2CYP3A4CYP3A5CYP3A7
SCHEMBL22988293 0.89 CYP1A2 (0.33) MAP4K3CYP1A2CYP3A4CYP3A5CYP3A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP claimed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN claimed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO claimed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 MAP4K3 1403/4885CCNT1 927/4885CCNK 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.